Act Now or Lose Out: Elevance Health Lawsuit Deadline Looms for Investors

The clock is ticking for investors who lost money in Elevance Health (formerly Anthem, Inc.) due to alleged financial misstatements tied to a Medicaid “acuity shift” fraud. With a critical July 11, 2025 deadline approaching, the window to seek recovery through the ongoing class action lawsuit is narrowing. This article explains why immediate action is essential—and how investors can capitalize on material misrepresentations that cost shareholders billions.

The Medicaid Acuity Shift Fraud: A Hidden Cost Time Bomb

At the heart of the lawsuit is a simple but devastating truth: Elevance Health allegedly misled investors about its Medicaid business risks. During the April 18, 2024 to October 16, 2024 period, the company failed to disclose that post-pandemic Medicaid eligibility redeterminations were removing healthier members from its rolls, leaving behind a population with far higher medical needs (acuity) and utilization of services like home health, radiology, and durable medical equipment.

This acuity surge, the lawsuit claims, outpaced premium rates negotiated with states and rendered Elevance’s financial guidance grossly inaccurate. Despite this, executives allegedly assured investors that premium rates and cost trends were sufficient to manage risks—a claim that unraveled in two seismic disclosures:

• July 17, 2024: Elevance revealed unexpectedly elevated Medicaid utilization, triggering a 5.8% stock plunge (losing $32.21/share).
• October 17, 2024: A 13.7% EPS miss and an 11.3% slash to 2024 guidance sent shares down another 10.6% ($52.61/share lost).

Why This Is a Game-Changer for Affected Investors

The lawsuit, Miller v. Elevance Health, Inc. (No. 25-cv-00923), is backed by proven litigation powerhouses like Robbins Geller Rudman & Dowd LLP (which secured a record $7.2 billion recovery in the Enron case) and Bernstein Litowitz Berger & Grossmann LLP (BLB&G), known for $40+ billion in recoveries. These firms are not here to “make a statement”—they’re here to maximize payouts for wronged investors.

Key takeaways for shareholders:
1. Deadline is Final: The July 11, 2025, lead plaintiff deadline is non-negotiable. Only investors who file motions by this date can seek leadership in the case. Even those not pursuing lead plaintiff status must act swiftly to enroll in the class.
2. Recoveries Are Real: Similar securities fraud cases have returned billions. For example, BLB&G recovered $2.3 billion for investors in the Volkswagen emissions scandal and $1.2 billion in the Boeing 737 MAX case.
3. No Upfront Costs: Representation is on a contingency fee basis—meaning investors pay nothing unless there’s a recovery.

How to Act Before It’s Too Late

Investors who purchased Elevance shares during the class period should:
- Contact Lead Counsel: Reach out to Robbins Geller (ross@bfalaw.com) or BLB&G (scott.foglietta@blbglaw.com) to submit claims or express interest in lead plaintiff status.
- Document Losses: Compile trade confirmations or account statements to quantify losses.
- Stay Informed: Monitor the case docket (S.D. Ind. No. 25-cv-00923) for updates on motions and settlement talks.

The Bottom Line: Act Now—or Write Off Your Losses Forever

Elevance Health’s alleged fraud didn’t just hurt its stock—it betrayed investor trust. With the July 11 deadline fast approaching, the path to recovery is clear: act immediately to join the class or seek lead plaintiff status. This is not a gamble—it’s a chance to hold Elevance accountable and reclaim what was taken through material misstatements.

The clock is ticking. Don’t let another minute pass.

*Data visualization note: The